NEWARK, CA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended ...
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
How does the size of this sale compare to Dr. Molina’s historical open-market transactions? This 9,514-share sale is the largest direct open-market sale by Dr. Molina to date, exceeding his previous ...
Goldman Sachs analyst Richard Law initiated coverage of Protagonist Therapeutics (PTGX) with a Neutral rating and $47 price target Both of the company’s Phase 3 assets can succeed commercially, but ...
Protagonist Therapeutics has shared a closer look at midphase data on its Johnson & Johnson-partnered oral peptide psoriasis drug candidate. The efficacy fell short of the high bar set by injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results